Nxera Pharma Slashes Executive Bonuses Following 2025 Results

The latest update is out from Sosei Group ( (JP:4565) ).

Nxera Pharma has moved to sharply cut performance-linked remuneration for its top executives following the disclosure of its full-year 2025 financial results. The company said the decision underscores its commitment to disciplined capital allocation and long-term value creation as it prioritizes investment in its development pipeline and commercial operations.

Under the revised pay structure, the Representative Executive Officer and President will see an 85% reduction in their performance-linked bonus, while Executive Officers will face a 70% cut. The reductions will apply from January through December 2026, signaling tighter alignment between executive compensation and company performance for shareholders and other stakeholders.

The most recent analyst rating on (JP:4565) stock is a Hold with a Yen804.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.

More about Sosei Group

Nxera Pharma is a technology-driven biopharmaceutical company focused on developing specialty medicines to address unmet medical needs in Japan and globally. It operates a next-generation commercial business in Japan and the broader APAC region, advancing an internal and partnered pipeline powered by its NxWave GPCR structure-based drug discovery platform, with key hubs across Japan, Europe and South Korea.

Average Trading Volume: 875,488

Technical Sentiment Signal: Sell

Current Market Cap: Yen80.36B

Learn more about 4565 stock on TipRanks’ Stock Analysis page.